What Does a p63 Positive Result Mean for a Diagnosis?

A p63 positive result on a pathology report means the tissue sample contains cells that express the p63 protein, a marker pathologists use to identify specific cell types and narrow down what kind of tumor they are looking at. In most contexts, p63 positivity points toward squamous or basal cell origin, because p63 is naturally expressed in the basal layer of skin, the lining of the mouth, the prostate, the bladder, the breast, and other epithelial tissues. But the meaning of “p63 positive” shifts dramatically depending on which organ the sample came from and what question the pathologist is trying to answer.

Why Pathologists Test for p63

p63 is a protein closely related to the well-known tumor suppressor p53. It plays a central role in the development and maintenance of epithelial tissues, the layered sheets of cells that line your organs and cover your skin. During embryonic development, p63 acts as a molecular switch that tells surface cells to begin stacking into protective layers. In mature tissue, it keeps the bottom-most “basal” cells dividing so those layers can continuously renew themselves.¹ Because of this role, p63 shows up in very specific places in normal adult tissue: the nuclei of basal cells in the skin, breast, oral lining, prostate, and urinary tract, among others.²

That predictable distribution is what makes p63 so useful in pathology. When a pathologist stains a tissue sample with an antibody that binds to p63 and sees positive staining, it tells them the cells have a basal or myoepithelial identity. When staining is absent, it tells them those cell types are missing. In either case, the result helps them figure out whether a growth is benign or malignant, what kind of cancer it is, or where it came from.

How p63 Helps Diagnose Prostate Cancer

In the prostate, the logic of p63 staining runs in a somewhat counterintuitive direction. Normal prostate glands have an outer ring of basal cells that stain positive for p63. Prostate cancer (adenocarcinoma) arises from the inner luminal cells and loses that basal cell layer entirely. So a pathologist looking at a suspicious cluster of glands on a biopsy uses p63 as part of a “basal cell cocktail” alongside another marker called 34βE12. If those glands show no p63 staining and no 34βE12 staining, the absence of basal cells supports a cancer diagnosis.³

In practice, pathologists often add a third marker called AMACR (also known as P504S), which stains cancer cells positively. The combination of AMACR-positive and p63-negative is a strong signal of prostate adenocarcinoma. One study of 40 confirmed malignant prostate cases found that none showed positive staining for p63 or the basal cell marker HMWCK, while the vast majority were positive for AMACR.⁴ This triple-stain approach is also used to evaluate prostate tissue after hormonal therapy, where residual or recurrent cancer can be harder to spot on routine staining alone.⁵

An important caveat: the absence of basal cell staining is not always conclusive for prostate cancer. Some benign conditions can also show patchy or absent basal cells, which is why pathologists combine p63 results with the overall architecture of the glands and other markers rather than relying on any single stain.³

Breast Lesions and the Myoepithelial Layer

In breast pathology, p63 serves a similar structural role but the clinical question is different. Normal breast ducts and lobules are surrounded by a layer of myoepithelial cells that stain positive for p63. When a pathologist needs to determine whether an abnormal growth is still contained within the duct (in situ, meaning it has not spread) or has broken through into surrounding tissue (invasive), they look for that myoepithelial layer. An intact ring of p63-positive cells around the abnormal growth means the lesion is still in situ. A disrupted or absent layer suggests invasion.⁶

This distinction matters enormously for treatment. In situ lesions are generally earlier-stage and carry a much better prognosis than invasive carcinomas. Studies have consistently shown that invasive breast carcinomas of all histological types and grades lack p63 staining in the tumor cells themselves, with expression limited to the surrounding normal tissue.⁷ p63 is also used to classify papillary lesions of the breast, helping distinguish benign intraductal papillomas from other growths.⁶

One potential trap: a small number of high-grade invasive breast carcinomas can express p63 in the tumor cells themselves, which could be mistaken for a myoepithelial layer and lead to a misclassification. This is an uncommon but recognized diagnostic pitfall that pathologists need to be aware of when evaluating core biopsies.⁸

Lung Cancer Subtyping

In lung pathology, p63 positivity usually indicates squamous cell carcinoma rather than adenocarcinoma. This distinction is clinically critical because the two subtypes respond to different treatments and carry different risks. When a lung tumor is well-differentiated, the pathologist can often tell the difference under the microscope without immunostains. But poorly differentiated lung cancers can look nearly identical, and p63 becomes part of a panel of markers used to classify them.⁹

Here, too, there is a significant pitfall. Some lung adenocarcinomas can show scattered p63-positive cells, which could be misread as evidence of squamous differentiation. This has led many pathology labs to supplement or replace p63 with a more specific marker called p40 (which detects only one isoform of the p63 protein). In studies comparing the two, p40 achieved higher specificity for squamous carcinoma in difficult cases. One study of malignant effusions found p40 had 90% specificity compared with a lower rate for p63 in distinguishing squamous carcinoma from adenocarcinoma.¹⁰

Skin Tumors and the Question of Origin

When a tumor appears in the skin, one of the first questions a pathologist faces is whether it started there or spread from somewhere else. p63 is remarkably useful in answering this. Primary skin tumors, including cutaneous adnexal neoplasms and squamous carcinomas, consistently express p63. Metastatic adenocarcinomas that have spread to the skin from internal organs do not. In one study of 79 cases, every primary cutaneous tumor tested positive for p63 while every metastatic carcinoma to the skin tested negative, yielding a perfect combination of sensitivity and specificity.¹¹ A separate study confirmed the same pattern: all primary cutaneous carcinomas expressed p63, and none of the metastatic adenocarcinomas did.¹²

This makes p63 one of the most reliable markers for a clinical scenario that comes up regularly: a patient with a known internal malignancy develops a new skin nodule, and the clinician needs to know whether it is a new primary skin lesion or a metastasis from the original cancer.

Salivary Gland and Head and Neck Tumors

Salivary gland tumors are notoriously complex, with dozens of subtypes that can be difficult to classify. p63 helps by marking the myoepithelial cells present in many of these tumors. In pleomorphic adenomas, basal cell adenomas, adenoid cystic carcinomas, and epithelial-myoepithelial carcinomas, p63 stains the myoepithelial component while leaving the luminal cells unstained.¹³ Myoepitheliomas and myoepithelial carcinomas express p63 throughout, which helps confirm their lineage. p63 has also been identified as a useful marker for recognizing the stripped-down myoepithelial cells in epithelial-myoepithelial carcinoma on cytology specimens, where those cells can be hard to identify.¹⁴

In the broader head and neck region, p63 positivity is a hallmark of squamous cell carcinoma, with studies showing expression in essentially all head and neck squamous cell carcinoma specimens tested. The dominant isoform expressed at the protein level in these tumors is ΔNp63α.¹⁵ A particularly tricky diagnostic scenario arises with sarcomatoid carcinomas of the head and neck, which can lose their obvious epithelial features and resemble soft tissue tumors. p63 staining can help detect hidden epithelial differentiation in these cases, though its usefulness is reduced by the fact that some benign soft tissue proliferations and mesenchymal tumors also stain positive for p63. Again, p40 tends to be more specific in this setting, staining far fewer non-epithelial lesions.¹⁶

When p63 Positive Is Misleading

No immunohistochemical marker is perfect, and p63 has known false-positive scenarios that can send a diagnosis in the wrong direction if the pathologist isn’t careful. One of the more striking examples involves diffuse large B-cell lymphoma. Lymphomas are cancers of immune cells, not epithelial cells, so you would not expect them to express a basal cell marker. Yet a case report documented a bladder mass in which p63 staining initially suggested a poorly differentiated urothelial carcinoma. Additional stains for immune cell markers ultimately confirmed the mass was actually a lymphoma.¹⁷ This is not a one-off curiosity; p63 can be positive in a meaningful fraction of diffuse large B-cell lymphoma cases, making it essential for pathologists to include lymphoma in the differential diagnosis when facing an aggressive, poorly differentiated tumor that stains for p63.

Similar false-positive issues arise in the lung (adenocarcinomas with scattered p63 cells mimicking squamous differentiation) and in the breast (rare invasive carcinomas expressing p63 in tumor cells). The common thread is that p63 is never interpreted in isolation. Pathologists use it as one piece of a panel that typically includes several other markers, each adding confirmatory or contradictory information. A single positive or negative result only acquires its meaning in the context of the full panel and the microscopic appearance of the tissue.

The Two Faces of p63 and Why Isoforms Matter

Part of the reason p63 can produce confusing results is that the gene actually encodes two families of protein isoforms with opposing functions. One version, called TAp63, promotes cell death and acts as a tumor suppressor, somewhat similar to p53. The other, called ΔNp63, blocks cell death and helps cells survive and proliferate.¹⁸ These two isoforms regulate distinct sets of genes and biological processes.¹⁹

Standard p63 immunohistochemistry, the kind used in routine diagnostic pathology, detects both isoforms without distinguishing between them. The p40 antibody, which is increasingly used alongside or instead of p63, specifically detects only the ΔNp63 isoform. This selectivity is why p40 tends to be more specific for squamous differentiation: it avoids picking up TAp63, which can be expressed more broadly in some tumor types. For the person reading a pathology report, the practical takeaway is that “p63 positive” is a broader, less specific label than “p40 positive,” and labs are gradually shifting toward p40 for situations where specificity matters most.

p63 as a Prognostic Marker

Beyond diagnosis, p63 expression sometimes carries prognostic information, though its utility varies by cancer type. In Merkel cell carcinoma, a rare and aggressive skin cancer, p63 positivity is associated with worse outcomes. One large study found that patients with p63-positive Merkel cell tumors had roughly double the cancer-specific mortality compared with patients whose tumors were p63-negative, and this remained significant even after adjusting for stage, age, and sex. Five-year cumulative mortality was about 63% in the p63-positive group versus about 31% in the p63-negative group.²⁰ That said, the researchers noted that the prognostic value did not hold up when looking at individual stages, limiting its clinical usefulness for guiding treatment decisions in any one patient.

In muscle-invasive bladder cancer, the picture is more complicated and the research has yielded conflicting signals depending on the study. One study found that elevated p63 was tied to worse overall survival, with a median of about 8 months compared with 27 months for lower p63 expression.²¹ Yet another study reported that reduced p63 expression was linked to unfavorable prognosis and that p63 positivity was associated with a luminal marker (GATA3) connected to more favorable disease.²² These seemingly contradictory findings likely reflect differences in molecular subtypes within bladder cancer and in how studies define and measure p63 expression levels. This is an area where the science is still being sorted out, and p63 is not yet a reliable standalone prognostic tool in bladder cancer.

When p63 Shows Up in Genetic Testing

Occasionally, p63 comes up not in the context of a tumor biopsy but in genetic testing for inherited conditions. Germline mutations in the TP63 gene (the gene that encodes the p63 protein) cause a group of developmental disorders that primarily affect the limbs, skin, and face. The best-known of these is EEC syndrome, characterized by split hands or feet, ectodermal abnormalities affecting the skin and hair, and facial clefts. Heterozygous mutations in p63 have been identified as the cause in multiple unrelated EEC families.²³ Other related syndromes caused by different mutations in the same gene include AEC syndrome (ankyloblepharon-ectodermal dysplasia-clefting), ADULT syndrome, Rapp-Hodgkin syndrome, and limb-mammary syndrome.²⁴

These conditions make biological sense given p63’s essential role in building stratified epithelia and developing limb structures during embryogenesis. The specific location of the mutation within the TP63 gene tends to predict which syndrome will develop, though there is some overlap.²⁵ If you encounter p63 in the context of genetic testing rather than a pathology report, the conversation is about one of these developmental disorders rather than cancer diagnosis.

Targeting p63 in Cancer Treatment

Because the ΔNp63 isoform helps certain cancer cells survive, resist drugs, and maintain stem-cell-like properties, researchers are investigating whether knocking it down could improve treatment outcomes. Early-stage laboratory work has shown that squamous cell carcinoma cells that express ΔNp63 depend on it for continued growth, providing proof of concept that reducing p63 levels could be a viable therapeutic strategy.²⁶ Combination approaches, such as simultaneously blocking two related growth-signaling pathways, appear more effective at reducing ΔNp63 levels than targeting either pathway alone. Histone deacetylase inhibitors, a class of drugs already approved for some cancers, have also shown the ability to sharply reduce ΔNp63 expression in lab settings.²⁶

None of this has reached the clinic yet. No approved cancer drugs specifically target p63, and the challenge is substantial: because p63 is a transcription factor (a protein that controls gene activity inside the nucleus), it is harder to drug than proteins sitting on a cell’s surface. Still, the research underscores that a p63-positive result on a pathology report may eventually carry therapeutic implications beyond diagnosis and prognosis, pointing toward tailored drug strategies for squamous cell cancers.²⁷

An Ancient and Conserved Gene Family

One reason p63 shows up in so many tissues and plays so many roles is its deep evolutionary history. The p53 gene family, which includes p53, p63, and p73, traces back over a billion years. A common ancestor of these three genes first appears in modern-day sea anemones, where it functions to protect reproductive cells from DNA damage. p63 and p73 split off from p53 relatively early in vertebrate evolution, with all three genes present in bony fish and increasingly specialized in higher vertebrates.²⁸ The structural features and functional activities of this gene family have been remarkably preserved across that span, which speaks to how fundamental p63’s roles are in maintaining epithelial integrity and responding to cellular stress. It is this deep conservation that explains why p63 is such a reliable marker for epithelial lineage across so many tissue types and clinical scenarios.